Article
Author(s):
Liraglutide (Saxenda) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with type 2 diabetes.
Medication Pearl of the Day: Liraglutide (Saxenda)
Indication: Liraglutide (Saxenda) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for type 2 diabetes as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least 1 weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia).
Insight:
Source: SAXENDA (liraglutide [rDNA origin] injection), (fda.gov)